Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial.

Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, Bulten J, Arbyn M.

JAMA. 2009 Oct 28;302(16):1757-64. doi: 10.1001/jama.2009.1569. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

PMID:
19861667
2.

Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.

Moore RA, Ogilvie G, Fornika D, Moravan V, Brisson M, Amirabbasi-Beik M, Kollar A, Burgess T, Hsu R, Towers L, Lo J, Matisic J, Brooks-Wilson A.

Cancer Causes Control. 2009 Oct;20(8):1387-96. doi: 10.1007/s10552-009-9365-4. Epub 2009 May 29.

3.

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T; Joint European Cohort Study.

BMJ. 2008 Oct 13;337:a1754. doi: 10.1136/bmj.a1754.

4.

Cervical cancer screening following prophylactic human papillomavirus vaccination.

Franco EL, Cuzick J.

Vaccine. 2008 Mar 14;26 Suppl 1:A16-23. Review.

PMID:
18642468
5.

Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.

Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P.

Int J Cancer. 2008 Sep 15;123(6):1344-9. doi: 10.1002/ijc.23670.

6.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

PMID:
18364502
7.

Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3.

Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P.

Eur J Cancer. 2008 Mar;44(4):565-71. doi: 10.1016/j.ejca.2007.12.002. Epub 2008 Jan 8.

PMID:
18248809
8.

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J.

N Engl J Med. 2007 Oct 18;357(16):1589-97. Erratum in: N Engl J Med. 2008 Oct 9;359(15):1637. Johansson, Bo [added].

9.

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group.

N Engl J Med. 2007 Oct 18;357(16):1579-88.

10.

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ.

Lancet. 2007 Nov 24;370(9601):1764-72. Epub 2007 Oct 4.

PMID:
17919718
11.

The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective.

Giorgi-Rossi P, Segnan N, Zappa M, Naldoni C, Zorzi M, Confortini M, Merito M, Cuzick J, Ronco G; NTCC Working Group.

Int J Cancer. 2007 Dec 15;121(12):2729-34.

12.

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.

Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M.

BMJ. 2007 Jul 7;335(7609):28. Epub 2007 May 21.

13.
14.

Is HPV testing with cytological triage a more logical approach in cervical cancer screening?

Franco EL, Ferenczy A.

Lancet Oncol. 2006 Jul;7(7):527-9. No abstract available.

PMID:
16814203
15.

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial.

Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J; ARTISTIC Trial Study Group.

Br J Cancer. 2006 Jul 3;95(1):56-61. Epub 2006 Jun 13.

16.
17.

Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review.

Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, Saville AM.

Lancet. 2006 Jan 14;367(9505):122-32. Review.

PMID:
16413876
18.

Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.

Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M.

Br J Cancer. 2005 Oct 17;93(8):862-7.

19.

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D.

Obstet Gynecol. 2004 Feb;103(2):304-9. Review.

PMID:
14754700
20.

Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P.

Lancet. 2003 Dec 6;362(9399):1871-6.

PMID:
14667741

Supplemental Content

Support Center